Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Goodwill (2018 - 2025)

Historic Goodwill for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $14.6 million.

  • Revolution Medicines' Goodwill changed 0.0% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $14.6 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Revolution Medicines reported Goodwill of $14.6 million as of Q3 2025, which was down 0.0% from $14.6 million recorded in Q2 2025.
  • Revolution Medicines' Goodwill's 5-year high stood at $14.6 million during Q1 2021, with a 5-year trough of $14.6 million in Q1 2021.
  • For the 5-year period, Revolution Medicines' Goodwill averaged around $14.6 million, with its median value being $14.6 million (2021).
  • Data for Revolution Medicines' Goodwill shows a peak YoY increase of 0.0% (in 2021) and a maximum YoY decrease of 0.0% (in 2021) over the last 5 years.
  • Revolution Medicines' Goodwill (Quarter) stood at $14.6 million in 2021, then changed by 0.0% to $14.6 million in 2022, then changed by 0.0% to $14.6 million in 2023, then changed by 0.0% to $14.6 million in 2024, then changed by 0.0% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q3 2025, $14.6 million for Q2 2025, and $14.6 million during Q1 2025.